Yahoo Finance StockCall Scrutinizes PFE, MRK, JNJ, ABBV, and ZGNX
StockCall.com Provides Stock Research on Pfizer Inc., Merck & Co. Inc., Johnson & Johnson, AbbVie Inc., and Zogenix Inc.
New York City, New York -- (May 15, 2013)
According to a report released by IMS Institute of Healthcare Informatics recently, U.S. spending on medicines fell 1% in 2012. Per capita spending on medicines fell 3.5%, the report also showed. The report further highlights the impact increasing generic competition is having on major drug manufacturers. With patent on several blockbuster drugs scheduled to expire over the next four years, major drug manufacturers can expect further competition from generic drug makers. The key for major drug manufacturers will be to boost their product pipeline. Shares of major drug manufacturers ended mostly higher on Tuesday, tracking gains in the broad market. Among the major movers were Pfizer Inc. (NYSE:PFE - News), Merck & Co. Inc. (NYSE:MRK - News), Johnson & Johnson (NYSE:JNJ - News), AbbVie Inc. (NYSE:ABBV - News), and Zogenix Inc. (NASDAQ:ZGNX - News). StockCall reviewed the Drug Manufacturers – Major industry and chose PFE, MRK, JNJ, ABBV, and ZGNX for its technical coverage. These free reports can be seen for free at
Pfizer Inc. closed its Tuesday’s session at $29.40, up 0.10 percent from its previous close. The stock shows this bullish trend may go as high as $31.10 in the coming trading sessions. Upon breaching this level, it may go up to $31.35 level. Pfizer traded 32.73 million shares during yesterday’s session, and the stock oscillated in the range of $29.28 and $29.50. The stock has appreciated 29.8 percent in the past 52 weeks while its YTD gain stands at 18.12 percent. Download the free research on PFE by signing up now at
www.StockCall.com/PFE051513.pdf
Merck & Co. Inc. made an upward movement with 1.04 percent gain in its latest session. The company’s stock ended at $46.65 and its highest price point for the session stood at $46.77. In the past 12 months, the stock has grown 22.67 percent while its YTD gain stands at 14.79 percent. Merck trades at beta of 0.58 which implies low volatility. It traded 13.42 million shares during yesterday’s session in comparison to its regular daily volume of 15.03 million shares. Register for today’s free analysis on MRK at
www.StockCall.com/MRK051513.pdf
Johnson & Johnson extended its 52 weeks gain to 35.17 percent by closing its previous trading session 1.30 percent higher. The stock closed at $86.97, with trading volume of 10.36 shares. It is up 25.17 percent on a YTD basis. Johnson & Johnson is currently in a bullish mode and is expected to go up to $87.34 in the coming trading sessions. Its next resistance level is at $87.45. On the downside, it is expected to face its first support level at $85.60. The company traded in the range of $61.71 and $87.08 in the past 52 weeks. Free report on JNJ can be accessed by registering at
www.StockCall.com/JNJ051513.pdf
AbbVie Inc. is currently trading below its 20-days and 50-days moving average price but still is in a bullish mode. It also ended its latest session 1.82 percent higher at $45.35, further confirming the trend. AbbVie exchanged 5.76 million shares during the session. The stock has outperformed the broader markets and has gained 31.37 percent so far this year. However, it is likely to go up to $46.25 in the coming trading sessions. Its second resistance level is at $46.38. AbbVie commands market capitalization of $71.65 billion.Register withStockCall and download the research on ABBV for free at
www.StockCall.com/ABBV051513.pdf
Zogenix Inc. closed its Tuesday’ trading session with a steep downward movement, accompanied with above average volume. The stock ended at $1.65, down 5.17 percent from its previous close. It traded in the range of $1.62 and $1.74 during yesterday’s session. The company’s current market capitalization stands at $189.12 million. Its stock has gained 25.95 percent on a YTD basis while its 52 weeks decline stands at 13.61 percent. Read the full free research on ZGNX by signing up to StockCall at
www.StockCall.com/ZGNX051513.pdf
About StockCall.com
StockCall.com is a financial website where investors can have easy, precise and comprehensive research and opinions on stocks making the headlines. Sign up today to talk to our financial analyst at
Contact Person:
William T. Knight
Email: info@stockcall.com
Contact Number: (646) 396-9857 (9:00 am EST – 01:30 pm EST)
